296 results on '"XU Peng-peng"'
Search Results
2. Cholesterol efflux from C1QB-expressing macrophages is associated with resistance to chimeric antigen receptor T cell therapy in primary refractory diffuse large B cell lymphoma
3. Anti-metabolic agent pegaspargase plus PD-1 antibody sintilimab for first-line treatment in advanced natural killer T cell lymphoma
4. Study of electromagnetic interference suppression method for switched reluctance motor
5. Development of Blocking Function of Leakage Communication and Shaft Hoist Signal
6. Electrical Parameter Acquisition System Based on S7-300/200 PLC and Modbus Protocol
7. Treatment Outcomes and Prognostic Factors of Chemotherapy Combined With Radiation Therapy for Patients With Early-Stage Extranodal Natural Killer/T-Cell Lymphoma
8. Targeted agents plus CHOP compared with CHOP as the first-line treatment for newly diagnosed patients with peripheral T-cell lymphoma (GUIDANCE-03): an open-label, multicentre phase 2 clinical trial
9. Biological signatures of the International Prognostic Index in diffuse large B-cell lymphoma
10. Artificial intelligence in coronary computed tomography angiography
11. Genomic and transcriptomic profiling of peripheral T cell lymphoma reveals distinct molecular and microenvironment subtypes
12. The prognostic value of CT-derived fractional flow reserve in coronary artery bypass graft: a retrospective multicenter study
13. GPCR signaling contributes to immune characteristics of microenvironment and process of EBV-induced lymphomagenesis
14. Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trial
15. Human endogenous retroviruses as epigenetic therapeutic targets in TP53-mutated diffuse large B-cell lymphoma
16. Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma
17. Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study
18. Dual targeting PD-L1 and 4-1BB to overcome dendritic cell-mediated lenalidomide resistance in follicular lymphoma.
19. Coronary artery calcification and risk of mortality and adverse outcomes in patients with COVID-19: a Chinese multicenter retrospective cohort study
20. The first reported outbreak of an undetermined species of human infection with spotted fever group Rickettsia in Lu'an, China
21. SLC1A1 mediated glutamine addiction and contributed to natural killer T-cell lymphoma progression with immunotherapeutic potential
22. Optimal Measurement Sites of Coronary-Computed Tomography Angiography-derived Fractional Flow Reserve: The Insight From China CT-FFR Study
23. Therapeutic targeting miR130b counteracts diffuse large B-cell lymphoma progression via OX40/OX40L-mediated interaction with Th17 cells
24. Dynamic change of soluble interleukin-2 receptor distinguished molecular heterogeneity and microenvironment alterations in diffuse large B-cell lymphoma
25. Nonlinear intensity measurement for multi-source images based on structural similarity
26. Serial coronary CT angiography–derived fractional flow reserve and plaque progression can predict long-term outcomes of coronary artery disease
27. Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase III DEB study.
28. Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma
29. The effect of coronary calcification on diagnostic performance of machine learning–based CT-FFR: a Chinese multicenter study
30. Coronary computed tomography angiography derived flow fractional reserve: the state of the art
31. The influence of image quality on diagnostic performance of a machine learning–based fractional flow reserve derived from coronary CT angiography
32. Molecular heterogeneity of CD30+ diffuse large B-cell lymphoma with prognostic significance and therapeutic implication
33. Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial
34. Correction to: Serial coronary CT angiography–derived fractional flow reserve and plaque progression can predict long-term outcomes of coronary artery disease
35. CD47 overexpression is related to tumour‐associated macrophage infiltration and diffuse large B‐cell lymphoma progression
36. Targeted Agents Plus CHOP Compared with CHOP as the First-Line Treatment for Newly Diagnosed Patients with Peripheral T-Cell Lymphoma (GUIDANCE-03): An Open-Label, Multicentre Phase 2 Clinical Trial
37. CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis
38. CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis
39. The Prognostic Significance of CD79B Mutation in Diffuse Large B-Cell Lymphoma: A Meta-analysis and Systematic Literature Review
40. A novel lncRNA TCLlnc1 promotes peripheral T cell lymphoma progression through acting as a modular scaffold of HNRNPD and YBX1 complexes
41. Paclitaxel may inhibit migration and invasion of gastric cancer cells via nod‐like receptor family pyrin domain‐containing 3/caspase‐1/Gasdermin E mediated pyroptosis pathway
42. Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma
43. CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial
44. Molecular heterogeneity of BCL2/MYC double expressor lymphoma underlies sensitivity to histone deacetylase inhibitor.
45. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study
46. Prognostic Value of CT-FFR–Based Functional Duke Jeopardy Score in Patients With Suspected CAD
47. P1164: PEGARSPARGASE AND SINTILIMAB FOR NEWLY DIAGNOSED, ADVANCED STAGE NATURAL KILLER T-CELL LYMPHOMA, NASAL TYPE: AN OPEN-LABEL, SINGLE-ARM, PHASE 2 STUDY.
48. P1120: NOVEL TARGETED AGENTS IN COMBINATION WITH R-ICE (R-ICE-X) BASED ON GENOTYPING IN RELAPSED/REFRACTORY DLBCL.
49. Paclitaxel may inhibit migration and invasion of gastric cancer cells via nod‐like receptor family pyrin domain‐containing 3/caspase‐1/Gasdermin E mediated pyroptosis pathway.
50. Construction and validation of a differentiation scoring system for Spotted fever and Severe fever with thrombocytopenia syndrome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.